different receptors, multi-specific antibodies with the capacity to blockade of multiple targets or binding sites are showing improved therapeutic efficacy against cancer. Although "knobs-into-holes" technique is an efficient way to generate bispecific antibody with whole IgG-architecture, the efficacy of different heavy chain hetero-generation and the thermostability remain questionable. How to efficiently generate tetra-specific antibodies with more efficiency and stability is critical for the development of novel antibodies against cancer. Method: By using the structure-based computational design and longtime molecule dynamic simulation (5 ms), we have successfully developed a more efficient technique "Lock-and-key" to produce bispecific antibodies with more efficiency. Based on the parent EGFR antibody cetuximab, PD-L1 antibody atezolizumab, VEGF antibody bevacizumaband CTLA-4 antibody ipilimumab, EGFR tetra-specific antibody with whole IgG structure was designed. Results: With the benefits of multispecific antibody and whole IgG architecture, the EGFR tetra-specific antibody could specifically target EGFR, PD-L1, VEGF and CTLA-4, exhibiting potent anti-tumor efficacy than the combination of Cetuximab, Atezolizumab, Bevacizumab and Ipilimumab against NSCLC. Conclusion: "Lock-and-Key" technique could be a more promising method to produce the multi-specific antibody. More importantly, multi-specific antibody with whole intact IgG structure shows the advantages in cancer treatment. Antagonism of EGFR, PD-L1, VEGF and CTLA-4 through multi-specific antibody could be a promising anti-tumor strategy against NSCLC. Keyword: Multi-specific antibody, nonsmall cell lung cancer, tumor microenvironment
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The Efficacy and Safety of Bevacizumab Combined with Chemotherapy in the Treatment of DrugResistant SCLC X. Liu, S. Wang, Y. Cheng Jilin Cancer Hospital, Chang chun/CN Background: To explore the efficacy and safety of bevacizumab combined with chemotherapy in the treatment of drug-resistant small cell lung cancer (SCLC). Method: ---. Results: Of the 25 patients, 5 patients achieved partial response, 16 patients achieved stable disease, 4 patients achieved progressive disease, and no patients achieved complete response. The short-term effective rate was 20% (5/25) and the clinical benefit rate was 84% (21/25). PFS ranged from 2 months to 6.3 months, and the median PFS was 3.7 months. OS ranged from 5.0 to 12.0 months, with a median OS of 7.6 months. Five patients were still alive as of April 10, 2018. Common toxic and side effects are myelosuppression, alimentary tract reaction and alopecia. Conclusion: Bevacizumab combined with chemotherapy is effective in the treatment of drug-resistant small cell lung cancer, and its side effects are tolerable. However, due to the small number of cases observed, the results are biased to a certain extent, it is necessary to establish a large-scale, randomized, double-blind, controlled multi-center clinical study to further confirm its efficacy and safety. Background: Tumor mutation burden (TMB) is one of the strongest biomarker to stratify patients suitable for immunotherapy. However, the relationship between TMB and other typical genetic profile in lung adenocarcinoma is not clear. This study aimed to explore the genetic characteristics of non-small cell lung cancer (NSCLC) relationship between TMB and typical genetic profile in NSCLC patients. Method: Tumor tissue from 11 NSCLC patients in Jilin Cancer Hospital from July 2018 to August 2018 were tested by next generation sequencing (>500 target gene panel). 10 mutations/1 M basepairs as cut-off value, patients were divided into high tumor butden (TMB-High) and low tumor burden (TMB-Low). TMB relationship with lung cancer core genes (EGFR, ALK, ROS1, KRAS, BRAF, MET, RET and ERBB2), tumor suppressor genes, proto-oncogenes, and MSI was statistically analyzed. Results: Among the 11 NSCLC patients, 45% (5/11) of patients were TMB-low and 55% (6/11) of patients were TMB-high. 100% (11/11) of patients were microsatellite Stable (MSS) and there were no MSI patients. In TMB-low patients, there were 14 mutations in 9 tumor suppressor genes and 1 mutation in 1 proto-oncogene; 40% (2/5) of these patients had TP53 mutations; 60% (3/5) of these patients had 5 mutations in 4 lung cancer core genes (EGFR, MET, KRAS and ROS1). In TMB-high patients, there were 29 mutations in 17 tumor suppressor genes, 8 mutations in 4 proto-oncogenes; 100% (6/6) of these patients had TP53 mutations.; 83% (5/6) of these patients had 9 mutations in 4 lung cancer core genes. Background: EGFR-TKI has been the first choice for the treatment of advanced non-small cell lung cancer (NSCLC) patients with EGFRsensitive mutations. However, there is no evidence of the best treatment for patients who have EGFR rare mutations. (the mutation type except 19del and L858R). Tis retrospective study aimed to explore the clinical characteristic, curative effect and safety of EGFR rare mutations in advanced non-small cell lung cancer patients. Method: Data was collected from 1500 naive stage III B or IV non-small cell lung cancer (NSCLC) patients in Jilin Cancer Hospital from 2016 to 2018. Amplification Refractory Mutation System (ARMS) was used to detect EGFR mutations with exons 18, 19, 20 and 21. Results: 615 patients showed EGFR19del /L858R mutation, the mutation rate was 41% in 1500 advanced NSCLC patients; The rare EGFR mutations (G719X, 20Ins, 20Ins combined T790M, L861Q, S768I, G719X) rate was 3.4%(51/ 1500), in rare mutation type, 38 cases can be evaluated the treatment reponse, 15 cases accepted gefitinib or exetinib, 3 cases accepted alfatinib. Objective Response Rate (ORR) was 5.6%, disease control rate (DCR) was 61.1%, and the median progression-free survival (PFS) was 5.5 months; In rare mutations, the most mutations type were EGFR G719A and L861Q (39.4%, 15/51 cases), 8 cases accepted EGFR-TKI, ORR was 37.5%, the DCR was 50.0%, and the median PFS was 8.6 months. 20 cases accepted chemotherapy (including gemcitabine, docetaxel, pemetrexed and other platinum-based chemotherapy), ORR was 25.0%. DCR was 85.0% and the median PFS was 9.8 months. Conclusion: Chemotherapy showed more effective trend in rare mutation. Some rare mutation types were sensitive mutations, but the response of EGFR-TKI was poor. It is very necessary to explore the mechanism of EGFR rare mutations and develop new targeted therapies to improve prognosis. Keyword: NSCLC; EGFR rare mutations; EGFR-TKI; Chemotherapy
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